Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellectar BiosciencesCLRB -4.26%23 3-1 Month Momentum % is -10.76% as of Jul. 23, 2026. GuruFocus rates CLRB with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,388 Biotechnology companies, Cellectar Biosciences ranks better than 68.59% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-23), Cellectar Biosciences's 3-1 Month Momentum % is -10.76%.
The industry rank for Cellectar Biosciences's 3-1 Month Momentum % or its related term are showing as below:
CLRB's 3-1 Month Momentum % is ranked better than 68.59% of 1388
companies
in the Biotechnology industry
Industry Median: -12.625
vs CLRB: -10.76
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Cellectar Biosciences 3-1 Month Momentum % Related Terms
CLRB vs OTLC, PTN, LPCN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Cellectar Biosciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectar Biosciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Cellectar Biosciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences (CLRB) has a 3-1 Month Momentum % of -10.76% as of Jul. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cellectar Biosciences and its competitors. According to the industry distribution chart, Cellectar Biosciences ranks #436 out of 1388 companies in the Biotechnology industry, placing it in the top 31.4%.
Is Cellectar Biosciences' 3-1 Month Momentum % too high?
Cellectar Biosciences' current 3-1 Month Momentum % is -10.76%. Based on the distribution chart, Cellectar Biosciences ranks #436 out of 1388 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cellectar Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' 3-1 Month Momentum % compare to OTLC and PTN?
According to the Biotechnology industry distribution chart, Cellectar Biosciences ranks #436 out of 1388 companies for 3-1 Month Momentum %. This puts Cellectar Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Cellectar Biosciences and its competitors. Cellectar Biosciences's current 3-1 Month Momentum % is -10.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current 3-1 Month Momentum % of -10.76%. The current 3-1 Month Momentum % is -10.76%. Cellectar Biosciences' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current 3-1 Month Momentum % is -10.76% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
23GF Score
Get the complete analysis for CLRB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLRB has been successfully added to your 
